SCHEMBL462038

SCHEMBL462038

CCCCCC1CC1N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL462039 1.00
SCHEMBL2877408 1.00
SCHEMBL21746023 1.00
SCHEMBL19384130 0.97 ALOX5 (0.48)
SCHEMBL11881699 0.92
SCHEMBL28733096 0.85 SPHK1 (0.46)
SCHEMBL23879671 0.81 DPP4 (0.38)
Methylamine SCHEMBL27734108 0.81 ALOX5 (0.57)
SCHEMBL14616020 0.80
SCHEMBL726033 0.80 ALOX5 (0.61)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108530389-B Preparation method of 2-aryl cyclopropylamine compound 东北师范大学 2020-06-09 CN claimed
US-20160081947-A1 SELECTIVE LSD1 AND DUAL LSD1/MAO-B INHIBITORS FOR MODULATING DISEASES ASSOCIATED WITH ALTERATIONS IN PROTEIN CONFORMATION ORYZON GENOMICS S.A. (ES) 2016-03-24 US claimed
US-20150232436-A1 LYSINE DEMETHYLASE INHIBITORS FOR MYELOPROLIFERATIVE DISORDERS ORYZON GENOMICS S.A. (ES) 2015-08-20 US claimed
US-20140329833-A1 LYSINE DEMETHYLASE INHIBITORS FOR INFLAMMATORY DISEASES OR CONDITIONS ORYZON GENOMICS, S.A (ES) 2014-11-06 US claimed
US-20140296255-A1 LYSINE DEMETHYLASE INHIBITORS FOR THROMBOSIS AND CARDIOVASCULAR DISEASES ORYZONG GENOMICS, S.A. (ES) 2014-10-02 US claimed
US-20140256742-A1 LYSINE DEMETHYLASE INHIBITORS FOR DISEASES AND DISORDERS ASSOCIATED WITH FLAVIVIRIDAE ORYZON GENOMICS S.A. (ES) 2014-09-11 US claimed
US-20130303545-A1 CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS ORYZON GENOMICS S.A. (ES) 2013-11-14 US claimed
US-20100331575-A1 Processes For The Preparation Of Optically Active Intermediates ASTRAZENECA AB (SE) 2010-12-30 US claimed
US-7790927-B2 Using hypochlorite in water in presence of alkali metal hydroxide ASTRAZENECA AB (SE) 2010-09-07 US claimed
EP-2049463-A1 A PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE CYCLOPROPYLAMINES Astra Zeneca AB (SE) 2009-04-22 EP claimed
US-20080071114-A1 Processes For The Preparation Of Optically Active Intermediates ASTRAZENECA AB (SE) 2008-03-20 US claimed
WO-2008018823-A1 A PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE CYCLOPROPYLAMINES ASTRAZENECA AB (SE) 2008-02-14 WO claimed
US-11834406-B2 Conjugates of cell binding molecules with cytotoxic agents HANGZHOU DAC BIOTECH CO., LTD. (CN) 2023-12-05 US disclosed
US-11767294-B2 Conjugates of cell binding molecules with cytotoxic agents HANGZHOU DAC BIOTECH CO., LTD. (CN) 2023-09-26 US disclosed
WO-2023091932-A1 CANCER TREATMENT USING LSD1 INHIBITORS AND PLK1 INHIBITORS CARDIFF ONCOLOGY, INC. (US) 2023-05-25 WO disclosed
CN-111194306-B Methods and processes for preparing KDM1A inhibitors 伊美格生物科学公司 2023-05-16 CN disclosed
EP-1388535-A1 Acylated arylcycloalkylamines and their use as pharmaceuticals Aventis Pharma Deutschland GmbH (DE) 2004-02-11 EP disclosed
EP-1296938-A1 CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE Pfizer Limited (GB) 2003-04-02 EP disclosed
US-20020052370-A1 Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PFIZER, INC. 2002-05-02 US disclosed
WO-2002002513-A1 CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE PFIZER LIMITED (GB) 2002-01-10 WO disclosed